Medline posts best intraday gain after Q3 beat, $1B share buybacks

What happened

Medline reported Q3 2026 revenue of $7.9 billion, up about 10% year over year and $180 million above consensus, and adjusted earnings per share of $0.44, $0.09 above forecasts. It raised organic growth guidance, reaffirmed its full-year adjusted EBITDA outlook, and announced up to $1B in share buybacks.

Confirmed

Global impact / market context

Stronger sales and higher growth guidance suggest Medline expects demand to support revenue beyond the quarter. The buyback could use cash to reduce shares outstanding, potentially supporting earnings per share, while the unchanged adjusted EBITDA outlook limits evidence of a raised profit expectation.

Analyst inference

The reported beat was driven mainly by Supply Chain Solutions, which grew faster than Medline Brand. Adjusted EBITDA, a measure of operating earnings before certain costs, also exceeded consensus, partly due to tariff refunds; investors should distinguish those refunds from recurring sales performance.

Confirmed

What to watch

1. Check whether later results show organic growth within or above the raised guidance range, particularly in Supply Chain Solutions, the main contributor to this quarter’s sales beat. Analyst inference
2. Watch for details on when and how Medline will carry out the announced repurchase of up to $1B in Class A shares, including how much cash it uses. Proposed
3. Compare future adjusted EBITDA with the reaffirmed full-year outlook and assess whether growth is supported by sales rather than tariff refunds, which may not recur. Analyst inference

Evidence

• seekingalpha.com